Multicenter, Phase Ib/IIa Study on the Safety and Efficacy of Autologous Peptide-coupled Red Blood Cells in Patients with Relapsing Remitting Multiple Sclerosis
Latest Information Update: 08 Mar 2025
Price :
$35 *
At a glance
- Drugs CLS 12311 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Acronyms RED4MS
- Sponsors Cellerys
- 17 Jun 2024 Status changed from not yet recruiting to recruiting.
- 21 May 2024 Status changed from recruiting to not yet recruiting.
- 01 Aug 2023 New trial record